Farther Finance Advisors LLC increased its holdings in Henry Schein, Inc. (NASDAQ:HSIC – Free Report) by 58.9% during the third quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor owned 933 shares of the company’s stock after purchasing an additional 346 shares during the quarter. Farther Finance Advisors LLC’s holdings in Henry Schein were worth $68,000 at the end of the most recent quarter.
Several other institutional investors and hedge funds have also added to or reduced their stakes in the business. Cromwell Holdings LLC increased its holdings in shares of Henry Schein by 93.4% in the third quarter. Cromwell Holdings LLC now owns 352 shares of the company’s stock valued at $26,000 after buying an additional 170 shares in the last quarter. Summit Securities Group LLC acquired a new position in shares of Henry Schein in the 2nd quarter worth $31,000. Beach Investment Counsel Inc. PA acquired a new stake in shares of Henry Schein during the second quarter worth $37,000. Blue Trust Inc. lifted its holdings in shares of Henry Schein by 104.2% during the second quarter. Blue Trust Inc. now owns 931 shares of the company’s stock valued at $60,000 after purchasing an additional 475 shares during the last quarter. Finally, Mather Group LLC. boosted its position in shares of Henry Schein by 16.8% in the 2nd quarter. Mather Group LLC. now owns 1,502 shares of the company’s stock valued at $96,000 after purchasing an additional 216 shares during the period. 96.62% of the stock is owned by institutional investors and hedge funds.
Henry Schein Stock Down 1.2 %
Shares of Henry Schein stock opened at $67.46 on Wednesday. The stock has a 50-day simple moving average of $70.40 and a 200-day simple moving average of $69.63. Henry Schein, Inc. has a 52-week low of $63.67 and a 52-week high of $82.63. The firm has a market cap of $8.41 billion, a price-to-earnings ratio of 27.76, a P/E/G ratio of 1.95 and a beta of 0.87. The company has a debt-to-equity ratio of 0.46, a current ratio of 1.42 and a quick ratio of 0.90.
Analysts Set New Price Targets
A number of research firms have commented on HSIC. Baird R W raised shares of Henry Schein from a “hold” rating to a “strong-buy” rating in a research note on Monday, July 22nd. StockNews.com raised shares of Henry Schein from a “sell” rating to a “hold” rating in a research note on Thursday, November 7th. JPMorgan Chase & Co. cut their target price on shares of Henry Schein from $88.00 to $80.00 and set an “overweight” rating on the stock in a research note on Monday, August 12th. UBS Group decreased their target price on Henry Schein from $75.00 to $72.00 and set a “neutral” rating for the company in a research report on Wednesday, August 7th. Finally, Barrington Research reissued an “outperform” rating and set a $82.00 price target on shares of Henry Schein in a research report on Wednesday, November 6th. One investment analyst has rated the stock with a sell rating, six have issued a hold rating, five have assigned a buy rating and one has assigned a strong buy rating to the stock. According to MarketBeat.com, the stock has an average rating of “Hold” and an average target price of $77.50.
View Our Latest Stock Report on HSIC
Insider Buying and Selling
In other Henry Schein news, SVP Lorelei Mcglynn sold 21,035 shares of the firm’s stock in a transaction dated Friday, September 6th. The stock was sold at an average price of $69.30, for a total transaction of $1,457,725.50. Following the transaction, the senior vice president now directly owns 71,833 shares in the company, valued at $4,978,026.90. This trade represents a 0.00 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at the SEC website. 1.14% of the stock is currently owned by corporate insiders.
Henry Schein Company Profile
Henry Schein, Inc provides health care products and services to dental practitioners, laboratories, physician practices, and ambulatory surgery centers, government, institutional health care clinics, and other alternate care clinics worldwide. It operates through two segments, Health Care Distribution, and Technology and Value-Added Services.
Further Reading
- Five stocks we like better than Henry Schein
- How to Read Stock Charts for Beginners
- Home Depot Stock: Targeting 12% in 2024 and 25% More in 2025
- 3 Warren Buffett Stocks to Buy Now
- Is Tesla’s Valuation a Bubble or Backed by Real Growth?
- What Does a Stock Split Mean?
- Trucking Stocks Led the Pack Last Week: Can They Keep Rolling?
Receive News & Ratings for Henry Schein Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Henry Schein and related companies with MarketBeat.com's FREE daily email newsletter.